Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Transcode Therapeutics Inc
(NQ:
RNAZ
)
1.775
+0.005 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Transcode Therapeutics Inc
< Previous
1
2
3
Next >
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
November 07, 2022
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
October 26, 2022
Study provides additional support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
October 13, 2022
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trials
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results
November 15, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
September 30, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
September 23, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results
August 23, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138
August 05, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Over-allotment Option
July 13, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering
July 08, 2021
From
TransCode Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.